MarketCap
Facebook
X
Telegram
Taysha Gene Therapies Financial Ratios 2025-2011 | TSHA
Brief overview of Taysha Gene Therapies's multiples and efficiency
This overview follows the five latest available observations from 2021 through 2025.
Market valuation is represented by P/S 149.17x (median 32.32x), P/B 5.9x (median 5.56x). Multiples are on average 183.9% above their own medians. A substantial share of positive expectations may already be priced in.
The latest available business-quality ratios are ROE -44.1%, ROA -31.7%, ROCE -44.7%. Current return ratios are negative, materially weakening the fundamental profile.
Current PEG is 0.54x; the market pays comparatively little per unit of expected growth.
The time from paying for inputs to receiving cash rose from -119.2 days to -37.8 days. Cash turnover slowed.
Valuation takeaway
Taysha Gene Therapies's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.
Annual Financial Ratios Taysha Gene Therapies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-13.4 | -4.5 | -2.3 | -0.2 | -1.4 | -5.1 | - | - | - | - | - | - | - | - | - |
P/S |
149.2 | 47.7 | 16.9 | 12.1 | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.3 | -0.4 | -1.0 | -3.8 | -4.6 | -3.4 | - | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
1.23 B | 348 M | 215 M | 67.8 M | 209 M | 61.4 M | 150 K | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.34 | -0.36 | -0.61 | -3.67 | -4.59 | -3.66 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-11.3 | -3.9 | -3.0 | -0.4 | -1.1 | -1.3 | - | - | - | - | - | - | - | - | - |
PEG |
0.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
P/B |
5.9 | 5.6 | 3.5 | 32.0 | 2.5 | 1.2 | - | - | - | - | - | - | - | - | - |
P/CF |
-15.7 | -4.9 | -3.6 | -0.3 | -2.0 | -7.7 | - | - | - | - | - | - | - | - | - |
ROE % |
-44.14 | -124.85 | -148.88 | -17493.57 | -182.97 | -23.88 | - | - | - | - | - | - | - | - | - |
ROA % |
-31.75 | -55.68 | -64.59 | -131.47 | -81.57 | -23.18 | - | - | - | - | - | - | - | - | - |
ROCE % |
-44.75 | -127.87 | -96.67 | -17117.70 | -181.65 | -17.08 | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.6 | 1.8 | 1.8 | 1.0 | 1.8 | 36.2 | - | - | - | - | - | - | - | - | - |
DPO |
37.8 | 50.0 | 119.2 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-37.8 | -50.0 | -119.2 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Taysha Gene Therapies
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.12 | -0.09 | -0.09 | -0.08 | - | -0.1 | -0.09 | -0.1 | - | -0.93 | -0.38 | -0.28 | - | -0.65 | -0.85 | -1.32 | - | -1.35 | -1.09 | -0.87 | - | -1.28 | -1.95 | -0.5 | -0.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.12 | -0.1 | -0.09 | -0.08 | - | -0.1 | -0.09 | -0.1 | - | -0.13 | -0.36 | -0.26 | - | -0.61 | -0.82 | -1.29 | - | -1.33 | -1.08 | -0.87 | - | -1.28 | -0.37 | -0.51 | -0.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-84.87 | -93.60 | -97.88 | -131.75 | -92.65 | 145.75 | 240.77 | 377.88 | 422.56 | 174.72 | -168.56 | -334.00 | -451.89 | -488.35 | -262.44 | -171.94 | -72.77 | -78.76 | -50.74 | -30.96 | -16.59 | 809.34 | 838.28 | -2.16 | 825.93 | 22.96 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-48.09 | -48.13 | -48.23 | -55.89 | -40.33 | -100.14 | -116.14 | -123.05 | -107.32 | -131.12 | -95.26 | -95.41 | -78.07 | -99.30 | -92.43 | -81.66 | -51.34 | -57.16 | -44.12 | -29.29 | -16.11 | -7449.44 | -7650.29 | -2.10 | -7433.33 | -206.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-85.72 | -94.36 | -98.39 | -132.82 | -93.91 | -60.83 | 31.35 | 161.69 | 206.87 | -30.98 | -166.73 | -327.59 | -438.37 | -474.46 | -258.48 | -170.21 | -72.36 | -78.34 | -43.84 | -24.20 | -9.80 | 816.12 | 845.07 | -2.22 | 825.93 | 22.96 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.4 | 3.2 | 3.9 | 1.7 | 1.8 | 2.0 | 2.2 | 1.5 | 1.8 | 0.8 | 0.7 | 0.9 | 1.0 | 1.1 | 1.3 | 1.4 | 1.8 | 2.4 | 4.4 | 12.2 | 34.2 | 34.2 | 34.2 | 34.2 | 0.1 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
29.6 | 54.0 | 50.6 | 32.0 | - | 67.1 | 95.3 | 92.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | -54.0 | -50.6 | -32.0 | - | -67.1 | -95.3 | -92.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Taysha Gene Therapies, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
